# Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)

> **NCT01063660** · PHASE2 · COMPLETED · sponsor: **medac GmbH** · enrollment: 75 (actual)

## Conditions studied

- Acute Myeloid Leukaemia

## Interventions

- **DRUG:** Treosulfan

## Key facts

- **NCT ID:** NCT01063660
- **Lead sponsor:** medac GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2010-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01063660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01063660, "Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01063660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*